KMA warns that it will act decisively on Zuellig's monopolistic activity

Published: 2001-09-11 06:56:00

Updated: 2001-09-11 06:56:00

Considerable focus is being given to the proclamation of the Korea Medical Association (hereinafter refer to as KMA) that they would take all possible measures against Zuellig and Handok Pharmaceutical Corporation.

The Emergency Committee of the KMA announced in a statement titled 'For the e...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK